Combinostics provides advanced tools for data-driven diagnostics using heterogeneous patient data. The tools give the physician a holistic view of all patient data. The company is based on protected innovations developed at VTT Technical Research Centre of Finland.

Customer problem and our solution
Our technology is generic and our first application is in Alzheimer’s disease and other forms of dementia. Today, physicians are overwhelmed with information from multiple examinations such as various neuropsychological tests, blood tests and imaging tests. Diagnosis is subjective and does not make full use of the information in the data. This leads to a prolonged time before the correct diagnosis can be established, a period during which the patient typically undergo additional examinations at several follow-up visits.
Combinostics changes this. With our cloud-based clinical decision support tool, we extract biomarkers from images, we compute a disease profile for the patient by combining imaging data with all other patient data, and we compare the patient’s data with data from previously diagnosed patients. Results are presented in a clinical decision support system using Combinostics’ patented disease-state fingerprint-technology. The use of the system allows for more objective and consistent diagnostics, where physicians are able to make confident decisions also at earlier disease stages. Moreover, the approach supports the use of a step-wise diagnostic approach, where low cost tests are used first and where high cost diagnostic tests are performed only on the patients who will benefit most from them.
Our unique selling proposition include 1) for physicians - diagnose patients early and start treatment, 2) for healthcare providers - reduced cost due to fewer follow-up visits and less use of expensive diagnostic tests, and 3) for society – delayed hospitalization.

Target market and customers
Our initial target market will be memory clinics in Europe and the US. We will also target primary care in the Nordics and the UK. Market expansion will be through moving to primary care in other regions including the US, and through expansion to other geographical regions with initial focus on East Asia. In a later phase, there will be an expansion into other disease areas such as Parkinson’s disease and Multiple Sclerosis and later also to disease areas outside neurology.

Business model
Combinostics’ business model is to provide access to our decision support tool as a diagnostics service using a pay-per-use model. Combinostics’ tools uses cloud technology making the business easily scalable. The yearly global market for diagnostic tools in Alzheimer's and dementia is more than €1B.